Macrogol (Polyethylene Glycol) for Pediatric Constipation
For children with functional constipation, start polyethylene glycol (PEG) 3350 at 0.7-0.8 g/kg/day for maintenance therapy, with doses ranging from 0.3-1.5 g/kg/day based on response, and use 1-1.5 g/kg/day for disimpaction over 1-6 days until clear liquid stool is achieved.
Maintenance Therapy Dosing
The optimal maintenance dose for pediatric functional constipation is 0.7-0.8 g/kg/day 1, 2. This dosing achieves:
- Increased stool frequency from baseline 2.3 to 16.9 stools per week
- Improved stool consistency
- Reduced soiling episodes by 87% in affected children
- High palatability and patient satisfaction 2
Dose Adjustment Strategy
Start with 0.7 g/kg/day and adjust every 3 days based on response 2:
- Target: 2 soft stools per day (Bristol scale 3-4)
- Increase dose if <3 bowel movements per week
- Decrease dose if ≥3 bowel movements per day or diarrhea develops
- Effective range: 0.3-1.5 g/kg/day 1, 3
A lower starting dose of 0.3 g/kg/day is equally effective but requires more frequent dose adjustments (2-fold higher adjustment rate) and results in lower parental satisfaction 1. The higher initial dose of 0.7 g/kg/day provides faster symptom control with similar safety.
Disimpaction Dosing
For fecal impaction, use 1.5 g/kg/day for 3-6 days or until passage of clear liquid stool 4:
- Continue until disimpaction is confirmed (clear liquid stool passage)
- Success rate: 84-86% regardless of PEG formulation
- Most children achieve disimpaction within 6 days
Recent data shows clinicians often use higher doses (4.6-5.3 g/kg/day) for 1-2 day cleanouts 5, which is nearly 3-fold higher than recommended. While these aggressive regimens may work, the standard 1.5 g/kg/day approach over several days is safer and equally effective.
Age-Specific Considerations
Children Under 24 Months
Evidence is limited but supports safety 6:
- Dosing range: 0.45-1.1 g/kg/day for PEG 3350
- Adverse effects (diarrhea, abdominal pain) are transient
- No serious adverse events reported
- Lack of established optimal dosing requires careful titration
Children Over 24 Months
Standard dosing applies with excellent long-term safety 7:
- Mean treatment duration: 18.6 months without dose adjustment for weight gain
- No serious adverse events with prolonged use
- Sustained clinical improvement in bowel movements and symptoms
Formulation Selection
PEG 3350 (with or without electrolytes) and PEG 4000 are equally effective 4:
- PEG 4000: Better palatability (statistically significant) but similar compliance
- PEG 3350 + electrolytes: Theoretical advantage of lower electrolyte imbalance risk
- Both formulations: 84-86% disimpaction success, similar adverse event profiles
Flavored formulations improve palatability and correlate with better treatment compliance 8. The choice between formulations should prioritize local availability and patient preference.
Duration of Treatment
Continue maintenance therapy for at least 6 months 7:
- Long-term use (≥6 months) normalizes bowel movements without safety concerns
- Early discontinuation commonly results in relapse 3
- No need for dose adjustment due to weight gain during prolonged therapy
- Parents/caregivers report sustained satisfaction with extended treatment
Common Pitfalls to Avoid
- Starting too low: Beginning at 0.3 g/kg/day requires frequent adjustments and delays symptom control
- Premature discontinuation: Stopping before 6 months increases relapse risk
- Inadequate disimpaction: Must continue until clear liquid stool, not just symptom improvement
- Ignoring palatability: Poor taste leads to non-compliance; consider flavored formulations
- Excessive dosing for cleanouts: Using >2 g/kg/day for home disimpaction lacks evidence and increases adverse effects 5
Expected Adverse Effects
Mild and transient side effects include 2, 4:
- Abdominal discomfort (most common)
- Vomiting
- Bloating (least likely to improve)
- Diarrhea (dose-dependent)
No serious adverse events have been reported in pediatric populations across multiple studies, including long-term use 6, 7.
Monitoring Response
Assess treatment success weekly:
- Success criteria: ≥3 bowel movements per week with no fecal soiling
- Track stool consistency using Bristol Stool Scale (target: type 3-4)
- Document soiling episodes
- Adjust dose every 3 days if targets not met